Friday, 20 Sep 2019

You are here

Industry Press Releases from EULAR19

Many of the great presentations from EULAR 2019 feature industry sponsored clinical trials.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Below is a collection of the industry press releases detailing the abstracts, authors and presentation times from EULAR 2019.

CompanyFeatured Abstract
 GileadEfficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results (oral #LB0001 4:25pm CET, 12 June, Hall 6)
 GileadEfficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results (oral #LB0003 8:00am CET, 15 June, Hall 7B)
 GileadFilgotinib in Patients with Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biologic DMARDs (bDMARD-IR) by Geographic Region and Race (poster #THU0173)
 GileadSelective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib Modulates the Disease-associated Whole Blood Transcriptional Profile of Patients with Active Rheumatoid Arthritis (poster #THU0194)
 GileadSafety and Efficacy of Filgotinib in Active Rheumatoid Arthritis by Prior Biologic DMARD Exposure in Patients with Prior Inadequate Response or Intolerance to Biologic DMARDs (bDMARD-IR) (poster #FRI0092)
 GileadFilgotinib, a Selective Janus Kinase 1 (JAK1) Inhibitor, Modulates Disease-associated Cytokines in Patients with Active Rheumatoid Arthritis (poster #FRI0113)
 GileadSafety and Efficacy of Filgotinib in Patients Aged 65 Years and Older: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biologic DMARDs (bDMARD-IR) (poster #FRI0154)
 Horizon Gout in the US: Significant Associations with Cardiovascular and Renal Disease Hospitalizations (SAT0446). Significantly higher rates of hospitalizations among gout patients for cardiac or acute renal events
 HorizonAnalysis of the Prevalence and Timing of Gout Co-Morbidity in Patients Undergoing Kidney Transplant (SAT0428)
 HorizonComorbidities in an Early Diagnosed Cohort of Uncontrolled versus Controlled Gout: Analysis of a Large Payer Database (SAT0429)
 Horizon Development of a Multivariable Improvement Measure for Gout (OP0051, June 12, 16:15)
 NovartisCosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis
 NovartisNovartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Believe in Vitamin D or Rituximab? (9.20.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – The End of Arthritis (9.13.19)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

RheumNow Podcast – Do’s and Don’ts in Spondylitis (9.5.19)

Dr. Jack Cush reviews the news and important research published in the last two weeks on RheumNow.com.

Influenza Vaccination Update

FDA's Vaccines and Related Biological Products Advisory Committee met in Silver Spring, Maryland, on March 6 and 22, 2019, to select the influenza viruses for the composition of the influenza vaccine for the 2019-2020 U.S. influenza season.

RheumNow Podcast - I Wanna New Drug (8-30-19)

Dr. Jack Cush vents on choosing new therapies in rheumatoid arthritis.